PARP1 and cardiomyopathy: In summary, these results provide a deeper understanding of the regulatory role of PARP-1 in diabetic heart inflammation and apoptosis, indicating that PARP-1 inhibition may be a feasible strategy for treating diabetic heart injury and cardiomyopathy.